Comparison Between Intravenous Hydrocortisone and Ondansetron in Prevention of Post Spinal Anesthesia Hypotension
Launched by NADA KAMEL ELGAMAL · Apr 9, 2025
Trial Information
Current as of July 01, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
According to the medication investigated in this study, patients will be divided into three equal groups (40 each). Patients will receive one of the following 15 minutes before spinal anesthesia:
1. Hydrocortisone 100 mg (H group)
2. Ondansetron 8 mg (O group)
3. An identical volume of sterile distilled water (Control group) (C group).
Spinal anesthesia will be performed under complete aseptic conditions with the patient seated, a 25-gauge Quincke spinal needle is used to administer 3.5 ml of a 0.5% hyperbaric bupivacaine together with 25 micrograms of fentanyl at the L3-L4 or L4-L5 level...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. ASA I and II (physical status according to American Society of Anesthesiologists).
- • 2. Patients aged 21 years or more.
- • 3. Either sex.
- • 4. Abdominal and lower limb operations.
- Exclusion Criteria:
- • 1. Patient refusal.
- • 2. hemodynamic instability
- • 3. Hematological diseases, bleeding or coagulation abnormality.
- • 4. Local skin infection and sepsis at site of spinal anesthesia
- • 5. neuromuscular diseases (as myopathies, myasthenia gravies...)
- • 6. Preexisting neurological deficit or psychiatric diseases.
- • 7. Known intolerance to the study drugs.
- • 8. patients already receiving any of the study drugs.
- • 9. diabetic patient.
About Nada Kamel Elgamal
Nada Kamel Elgamal is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical standards, the organization oversees a diverse portfolio of clinical trials aimed at evaluating the safety and efficacy of new treatments across various therapeutic areas. By fostering collaboration among researchers, healthcare professionals, and regulatory bodies, Nada Kamel Elgamal strives to contribute to the global body of medical knowledge and improve healthcare practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Port Said, , Egypt
Patients applied
Trial Officials
Magdy Ali Omera, prof. of Anesthesia and ICU
Study Chair
Port Said University, Faculty of Medicine, Department of Anesthesia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported